Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regula

U.S. stocks mixed: Dow slipped 0.1%, Nasdaq rose 0.7%, S&P 0.3%; tech led gains, energy fell, wh

Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript

Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to

Xenetic Biosciences plans to acquire Santersus in an all-stock deal, forming Santersus Bio to tackle

U.S. stocks edged higher as strong retail sales lifted sentiment; utilities gained, energy fell, oil

Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market ses

Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on t

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.41) per share. This is a 8.89 per

Expanded collaborative research initiatives reinforce the Company's long-term DNase development stra

This approval follows positive preclinical results that demonstrated significant improvement of CAR

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targ

New preclinical and translational findings position DNase I as a potentially transformative adjunct

New preclinical and translational findings position DNase I as a potentially transformative adjunct

Advancements across investigator-initiated studies, translational research and manufacturing activit

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.20) per share. This is a 66.1 per

FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xeneti

Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Fr

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the anal

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in d

Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Ainos (NASDAQ: AIMD - Get Free Report) are

Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a large growth in sh

Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO -

Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - G

Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a significant declin

Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In F

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceu

FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xen

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the anal

Continued execution on collaborations and exploratory investigator-initiated studies with institutio

Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companie

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceu

FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xene

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names h

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the anal

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studi

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement wi

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the anal